Gastrointestinal Cancer | Specialty

Dr. Larson on Ongoing Trials in Colorectal Cancer

November 9th 2017

Tim G. Larson, MD, oncologist, Minnesota Oncology, discusses ongoing trials in colorectal cancer (CRC).

Dr. Abou-Alfa on the Ongoing Impact and Role of Regorafenib in HCC

November 9th 2017

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the ongoing role and impact of regorafenib (Stivarga) in the paradigm of hepatocellular carcinoma (HCC) in an interview during the 2017 Chemotherapy Foundation Symposium.

Dr. O'Neil on Left-Sided Versus Right-Sided CRC

November 9th 2017

Bert O'Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses left-sided versus right-sided colorectal cancer (CRC).

Dr. Truty on Challenges With Treating Patients With Pancreatic Cancer

November 7th 2017

Mark J. Truty, MD, MS, assistant professor of surgery, Mayo Clinic, discusses challenges with treating patients with pancreatic cancer.

International Panel Describes Evolving Challenges in HCC

November 2nd 2017

Although new therapies are being rapidly introduced in the hepatocellular carcinoma field after years of clinical trial disappointments, clinicians face many challenges when treating patients with this malignancy, including delays in diagnosis and comorbidities.

Dr. Bekaii-Saab on the Response Rate of Pembrolizumab in MSI-H CRC

November 1st 2017

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the response rate of pembrolizumab (Keytruda) for patients with microsatellite instability-high (MSI-H) colorectal cancer (CRC).

CDK4/6 Inhibitors Explored in KRAS-Mutant Cancers

October 31st 2017

A new generation of more selective inhibitors of CDK4 and CDK6 has entered the clinic in combination therapies for patients with breast cancer. These agents also are being investigated in patients with KRAS-mutant malignancies.

Challenging Case Teaches Oncology Fellow the Power of Hope

October 30th 2017

Advanced esophageal cancer is a highly lethal malignancy and often spreads despite aggressive therapy.

Novartis to Add Lutathera to Portfolio in Planned $3.9-Billion Deal

October 30th 2017

Novartis has announced a planned $3.9-billion acquisition of Advanced Accelerator Applications, a radiopharmaceutical company that develops, produces, and commercializes Molecular Nuclear Medicines.

Treatment Modalities Evolving in Pancreatic Cancer

October 26th 2017

Mark J. Truty, MD, discusses sequencing treatments and advances in imaging technology in pancreatic cancer.

Cabozantinib Improves Survival in Phase III HCC Trial

October 17th 2017

Cabozantinib (Cabometyx) improved overall survival versus placebo in patients with advanced hepatocellular carcinoma who have previously received sorafenib (Nexavar), meeting the primary endpoint of the phase III CELESTIAL trial.

Dr. Ross on Biomarker Research Development in Liver Metastasis

October 11th 2017

Merrick I. Ross, MD, professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses biomarker research development for patients with liver metastasis.

Dr. Schmoll on the Toxicity of the CHARTA Study in CRC

October 10th 2017

Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/Oncology, University Hospital Halle, discusses the toxicity of the CHARTA study for patients with colorectal cancer (CRC).

PEGPH20: Future Directions in Pancreatic Adenocarcinoma

October 10th 2017

PEGPH20: A Novel Agent for Pancreatic Adenocarcinoma

October 10th 2017

Pancreas Cancer Treatment Forecast

October 10th 2017

Pancreas Cancer: Investigational Targeted Approaches

October 10th 2017

Clinical Research in the Treatment of Pancreas Cancer

October 10th 2017

Management of Borderline Resectable Pancreas Cancer

October 10th 2017

Neoadjuvant Therapy Recommendations in Pancreas Cancer

October 10th 2017